Warning AbbVie Inc. (ABBV) pessimists! Glenn Tilton just Invested in 5,400 shares.; Align Technology (ALGN) Sellers Decreased By 10.19% Their Shorts

June 29, 2018 - By Jerrie Dane

Align Technology, Inc. (NASDAQ:ALGN) Logo

Align Technology Inc (NASDAQ:ALGN) had a decrease of 10.19% in short interest. ALGN’s SI was 1.72M shares in June as released by FINRA. Its down 10.19% from 1.91 million shares previously. With 887,900 avg volume, 2 days are for Align Technology Inc (NASDAQ:ALGN)’s short sellers to cover ALGN’s short positions. The SI to Align Technology Inc’s float is 2.3%. The stock decreased 0.07% or $0.23 during the last trading session, reaching $343.57. About 414,888 shares traded. Align Technology, Inc. (NASDAQ:ALGN) has risen 125.29% since June 29, 2017 and is uptrending. It has outperformed by 112.72% the S&P500. Some Historical ALGN News: 04/04/2018 – Align Technology Introduces Invisalign Clear Aligners for Phase 1 Treatment of Younger Patients With Early Mixed Dentition; 04/04/2018 – ALIGN TECHNOLOGY EXPANDS INVISALIGN® PRODUCT PORTFOLIO WITH NEW OPTIONS AND GREATER FLEXIBILITY TO TREAT A BROADER RANGE OF PATIENTS; 23/04/2018 – Orthodontic Supplies Market to Hit 8.9% CAGR to 2023, Led by Align Technology, Inc. (US), 3M Company (US), and Danaher Corporation (US); 25/04/2018 – Align Technology Announces China Food and Drug Administration Approval for the iTero Element Intraoral Scanner; 25/04/2018 – ALIGN TECHNOLOGY – IN APRIL , SDC ENTITIES INITIATED PROCEEDINGS SEEKING TO PRELIMINARILY & PERMANENTLY REQUIRE CO TO CLOSE EXISTING INVISALIGN STORES; 25/04/2018 – Align Technology Sees 2Q Rev $460M-$470M; 15/05/2018 – Sands Capital Management Buys 3.4% Position in Align Technology; 19/04/2018 – Align Technology Volume Jumps More Than Five Times Average; 30/05/2018 – Align Technology CEO Sees Growth in All Markets (Video); 05/03/2018 Kevin J. Dallas Joins Align Technology Board of Directors

Since February 19, 2018, it had 1 insider buy, and 10 insider sales for $26.70 million activity. 4,294 shares were sold by Michael Robert A., worth $512,853 on Wednesday, February 28. RICHMOND TIMOTHY J. sold 18,129 shares worth $2.15 million. 2,643 shares were sold by SEVERINO MICHAEL, worth $311,684 on Wednesday, February 28. The insider Schumacher Laura J sold $2.95 million. 70,928 shares were sold by CHASE WILLIAM J, worth $8.31 million on Wednesday, February 28. The insider SALEKI-GERHARDT AZITA sold 1,337 shares worth $157,458. GONZALEZ RICHARD A also sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 EPS, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98B for 11.86 P/E if the $1.97 EPS becomes a reality. After $1.87 actual EPS reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “AbbVie On A Roll, Buy AbbVie” on June 28, 2018, also Investorideas.com with their article: “AbbVie (NYSE: ABBV) and Calibr announce collaboration for next generation T-cell therapies” published on June 25, 2018, Seekingalpha.com published: “Galapagos -13% after AbbVie pulls out of cystic fibrosis development plans” on June 28, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Fool.com and their article: “Bad News Delivers a Decisive Blow to Galapagos NV” published on June 29, 2018 as well as Seekingalpha.com‘s news article titled: “More Thoughts On AbbVie’s Rova-T Implosion” with publication date: June 06, 2018.

The Abbvie Inc’s director Glenn Tilton invested in – 5,400 shares of Abbvie Inc, calculated based on the stock price per share of $91.9 per every share. These insider shares had a value of precisely $496,274 U.S Dollars. At present, Glenn Tilton owns 39,735 shares which are equivalent to around 0.00% of the company’s total market capitalization. This deal was reported on June 29, 2018 and is already filed with the (SEC). The legal 4F filing is free at your disposal for review to the public here.

Among 14 analysts covering AbbVie (NYSE:ABBV), 5 have Buy rating, 2 Sell and 7 Hold. Therefore 36% are positive. AbbVie has $15700 highest and $78 lowest target. $116.18’s average target is 24.27% above currents $93.49 stock price. AbbVie had 28 analyst reports since January 4, 2018 according to SRatingsIntel. Credit Suisse maintained AbbVie Inc. (NYSE:ABBV) on Friday, June 22 with “Sell” rating. As per Tuesday, January 16, the company rating was maintained by Jefferies. Morgan Stanley maintained the shares of ABBV in report on Tuesday, January 30 with “Equal-Weight” rating. Argus Research maintained the stock with “Buy” rating in Friday, February 2 report. Argus Research maintained it with “Buy” rating and $130 target in Monday, June 11 report. BMO Capital Markets maintained AbbVie Inc. (NYSE:ABBV) rating on Wednesday, May 23. BMO Capital Markets has “Underperform” rating and $78 target. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Monday, February 26. Jefferies has “Buy” rating and $145.0 target. Cowen & Co maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, January 26. Cowen & Co has “Buy” rating and $130.0 target. The firm has “Neutral” rating given on Friday, June 1 by PiperJaffray. The rating was downgraded by BMO Capital Markets to “Underperform” on Tuesday, January 30.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $141.55 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 23.51 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It dropped, as 61 investors sold AbbVie Inc. shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Fidelity Natl Inc stated it has 207,950 shares or 2.91% of all its holdings. Glenview Bank Trust Dept owns 33,965 shares. 28,524 were reported by Loudon Investment Limited. Wealth Architects Limited Liability holds 4,262 shares. North Star Management holds 0.68% or 60,168 shares. 447,000 were accumulated by Eventide Asset Mngmt Ltd Company. The New York-based Hartwell J M Partnership has invested 0.1% in AbbVie Inc. (NYSE:ABBV). Schmidt P J Inv Management owns 75,760 shares. Atlas Browninc invested in 30,592 shares or 0.53% of the stock. Novare Capital Limited Liability Company invested 0.81% of its portfolio in AbbVie Inc. (NYSE:ABBV). Smithbridge Asset De has invested 1.9% in AbbVie Inc. (NYSE:ABBV). Summit Fincl Wealth Lc owns 43,972 shares for 3.1% of their portfolio. Capital Inv Advsr Ltd Liability reported 0.17% of its portfolio in AbbVie Inc. (NYSE:ABBV). Stock Yards Bank & Trust And Tru Com accumulated 41,281 shares. 40,191 are owned by Quantbot Technology Limited Partnership.

The stock increased 1.15% or $1.06 during the last trading session, reaching $93.49. About 2.76M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 29, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 05/04/2018 – AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis; 25/05/2018 – AstraZeneca: Evidence of the Benefit That Imfinzi Can Offer Lung Cancer Patients; 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer; 10/04/2018 – Oncolytics Biotech: Combination Therapy With REOLYSIN(R), Keytruda(R) and/or anti-CD73 Immunotherapy Led to Rejection of Pre-Established Tumors; 11/04/2018 – MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU; 24/05/2018 – IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMlNATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint; 01/05/2018 – AbbVie: Tender Offer and Withdrawal Rights Will Expire at Midnight ET May 29, 2018; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 08/05/2018 – ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE® IL-12 AND KEYTRUDA® (PEMBROLIZUMAB) FOR TRIPLE NEGATIVE BREAST CANCER; 07/03/2018 – EMA – PRELIMINARY REVIEW OF EVIDENCE INDICATES IMMUNE REACTIONS OBSERVED IN REPORTED CASES MAY BE LINKED TO USE OF ZINBRYTA

Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing digital services. The company has market cap of $27.54 billion. The companyÂ’s Clear Aligner segment offers Invisalign Full, a treatment used for a range of malocclusion; Invisalign Teen treatment that addresses orthodontic needs of teenage patients, such as compliance indicators, compensation for tooth eruption, and six free single arch replacement aligners; and Invisalign Assist treatment for anterior alignment and aesthetically-oriented cases. It has a 109.1 P/E ratio. It also provides Invisalign Express (10 and 5) and Invisalign Lite/i7 treatments for orthodontic cases, non-comprehensive treatment relapse cases, or straightening prior to restorative or cosmetic treatments; Invisalign Go, a solution for general practitioner dentists (GPs) to identify and treat patients with mild malocclusion; SmileDirectClub aligners for minor tooth movement; custom clear aligner retainers used to maintain tooth position and correct minor relapse; and SmartTrack, a custom-engineered material that delivers force for orthodontic tooth movements.

Investors sentiment decreased to 0.86 in Q1 2018. Its down 0.07, from 0.93 in 2017Q4. It dropped, as 41 investors sold Align Technology, Inc. shares while 216 reduced holdings. 77 funds opened positions while 143 raised stakes. 60.14 million shares or 1.24% less from 60.90 million shares in 2017Q4 were reported. Guardian Life Ins Of America stated it has 166 shares. Hbk Sorce Advisory Ltd Liability Co holds 0.05% in Align Technology, Inc. (NASDAQ:ALGN) or 1,621 shares. Northwestern Mutual Wealth Management has 0% invested in Align Technology, Inc. (NASDAQ:ALGN) for 3,107 shares. Adirondack Company invested in 10 shares or 0% of the stock. Private Advisor Gp Ltd Liability Company reported 2,680 shares. Manufacturers Life Insur The reported 80,454 shares. Oakbrook Investments Limited Liability Corp reported 6,185 shares or 0.1% of all its holdings. Contravisory Investment Management Inc stated it has 25 shares or 0% of all its holdings. 16,554 were reported by Ing Groep Nv. Parametric Port Associate Ltd Liability Co holds 0.04% or 166,386 shares in its portfolio. Hightower Advisors Ltd Liability Company invested in 0.04% or 21,080 shares. Bb&T Secs Limited Liability Company reported 2,979 shares stake. Great West Life Assurance Co Can owns 0.05% invested in Align Technology, Inc. (NASDAQ:ALGN) for 76,816 shares. Gilder Gagnon Howe Ltd invested in 1.42% or 456,961 shares. Credit Suisse Ag reported 257,819 shares stake.

Among 12 analysts covering Align Tech (NASDAQ:ALGN), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Align Tech had 23 analyst reports since January 4, 2018 according to SRatingsIntel. Leerink Swann maintained Align Technology, Inc. (NASDAQ:ALGN) on Wednesday, January 31 with “Outperform” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, January 31 report. The stock has “Buy” rating by Credit Suisse on Wednesday, January 31. The stock of Align Technology, Inc. (NASDAQ:ALGN) earned “Outperform” rating by Credit Suisse on Friday, May 25. The stock has “Buy” rating by Credit Suisse on Thursday, January 4. The stock of Align Technology, Inc. (NASDAQ:ALGN) has “Equal-Weight” rating given on Thursday, April 26 by Morgan Stanley. The company was maintained on Thursday, April 26 by Stifel Nicolaus. The firm has “Overweight” rating given on Thursday, May 24 by PiperJaffray. The stock of Align Technology, Inc. (NASDAQ:ALGN) earned “Outperform” rating by Leerink Swann on Thursday, May 24. Robert W. Baird maintained the shares of ALGN in report on Thursday, April 26 with “Buy” rating.

Align Technology, Inc. (NASDAQ:ALGN) Institutional Positions Chart